CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Unveiling the Pathophysiology and Advancing Treatment Strategies for Steroid-Refractory Chronic GVHD
Graft-vs-host disease (GVHD) stands as a significant complication post-allogeneic hematopoietic cell transplantation (aHCT), with its chronic form, cGVHD, manifesting as a major long-term challenge. This article looks into the intricate pathophysiology of steroid-refractory cGVHD, highlights the limitations of conventional therapies, and elucidates the recent advancements in treatment options, including FDA-approved therapies, thereby offering new horizons for patient management and care.
Key Points:
- cGVHD is a common long-term complication post-aHCT, affecting multiple organs and significantly impairing quality of life.
- The pathophysiology of cGVHD involves dysregulation of B and T cells and a transition from inflammation to fibrosis, indicating a complex interplay of immune responses.
- Risk factors for cGVHD include prior aGVHD, older age, mismatched/unrelated donors, and stem cell source, among others.
- Conventional therapy for moderate to severe cGVHD includes high-dose steroids and calcineurin inhibitors, but less than 50% of patients respond adequately.
- Steroid-refractory cGVHD is defined by progression or lack of response to high-dose steroids, with treatment being highly individualized due to varied patient responses.
- Advancements in treatment include FDA-approved therapies like ruxolitinib, belumosudil, and ibrutinib, each targeting different pathways implicated in cGVHD.
- Ruxolitinib has demonstrated superiority in response rates and failure-free survival compared to best supportive therapy in clinical trials.
- Belumosudil showed high response rates in patients, including those who had prior treatment with ruxolitinib or ibrutinib.
- Ibrutinib, the first FDA-approved therapy for cGVHD, has shown effective responses in organ involvement and sclerotic features.
- Ongoing research and clinical trials continue to refine the understanding and management of steroid-refractory cGVHD, highlighting the need for personalized treatment approaches.
More than 26,000 allogeneic hematopoietic cell transplantations (alloHCTs)are performed annually worldwide.
More in Hematology
